Tag Archives: bmrn

FDA Panel Seen As Bad For BioMarin, Good For Sarepta

Wall Street analysts lowered the odds of success for BioMarin Pharmaceuticals’ (BMRN) muscular-dystrophy drug drisapersen on Wednesday in the wake of the FDA advisory committee vote late Tuesday. They delivered more mixed opinions on the implications for rivals Sarepta Therapeutics (SRPT) and PTC Therapeutics (PTCT). The FDA panel gave largely negative opinions of BioMarin’s drisapersen, or Kyndrisa, despite BioMarin’s assertion that the totality

BioMarin Drug’s Future In Doubt After FDA Panel Vote

A panel of outside experts called by the FDA gave largely negative feedback on BioMarin Pharmaceuticals’ muscular-dystrophy drug candidate Tuesday in a hearing that investors, patients and makers of rival drugs watched closely. There’s been no consensus on Wall Street as to whether the FDA will approve drisapersen, a drug that failed to hit its primary endpoint in two phase-two studies and one phase-three study. But BioMarin (BMRN) argued that the

Medivation Buying Breast-Cancer Drug From BioMarin

Drugmaker Medivation (MDVN) agreed to acquire a late-stage breast-cancer drug candidate from BioMarin Pharmaceutical (BMRN) Monday in a deal worth up to $570 million. Medivation is paying $410 million upfront for talazoparib, which is currently in phase three testing for advanced or metastatic breast cancer involving germline mutations of the BRCA gene. If the drug succeeds, BioMarin is due up to $160 million in milestone payments along with